{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:27:18Z","timestamp":1793608038068,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129181","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:40:06Z","timestamp":1789994406000},"page":"129181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Measles seropositivity in the era of two-dose measles vaccination in Ireland"],"prefix":"10.1016","volume":"92","author":[{"given":"Sumanta","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129181_bb0005","author":"European Centre for Disease Prevention and Control (ECDC)"},{"key":"10.1016\/j.vaccine.2026.129181_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.s172","article-title":"UK loses its measles elimination status","volume":"392","author":"Taylor","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.129181_bb0015","author":"The New Zealand Institute for Public Health and Forensic Science (PHF sScience)"},{"key":"10.1016\/j.vaccine.2026.129181_bb0020","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2026.31.9.2500313","article-title":"Cross-sectional seroprevalence study of measles antibodies among children to identify gaps in population immunity, Ireland, 2024","volume":"31","author":"Brady","year":"2026","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.129181_bb0025","series-title":"Prevalence of measles IgG antibodies in adults aged 18\u201334 years in Ireland, 2022","author":"Health pProtection sSurveillance Centre (HPSC)","year":"2023"},{"key":"10.1016\/j.vaccine.2026.129181_bb0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.vaccine.2017.12.002","article-title":"Declining measles antibodies in the era of elimination: Australia\u2019s experience","volume":"36","author":"Gidding","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129181_bb0035","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1016\/j.vaccine.2017.06.058","article-title":"An increasing, potentially measles-susceptible population over time after vaccination in Korea","volume":"35","author":"Kang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129181_bb0040","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1016\/j.vaccine.2023.03.009","article-title":"What\u2019s in a number? The value of titers as routine proof of immunity for medical students","volume":"41","author":"Charlton","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129181_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127931","article-title":"Limitations of serological screening for measles immunity in young health care workers in New Zealand","volume":"68","author":"Saha","year":"2025","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:41:30Z","timestamp":1793605290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"alternative-id":["S0264410X26009904"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129181","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measles seropositivity in the era of two-dose measles vaccination in Ireland","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129181"}}